Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for In Vivo Imaging

2021 ◽  
Author(s):  
Lin Zhang ◽  
Lingli Zhou ◽  
Hui Zhang ◽  
Yibin Zhang ◽  
Ling Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
In Vivo Imaging ◽  
Multidrug Resistant ◽  
Dna Aptamer

In vivo imaging of hepatocellular carcinoma using a glypican-3-binding peptide based probe

2017 ◽  
Author(s):  
Qi Zhang ◽  
Zhihao Han ◽  
Wancun Zhang ◽  
Zhiyu Qian ◽  
Yueqing Gu
Keyword(s):  
Hepatocellular Carcinoma ◽  
In Vivo Imaging ◽  
Binding Peptide

scholarly journals DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition

Theranostics ◽  
2015 ◽  
Vol 5 (9) ◽  
pp. 985-994 ◽  
Author(s):  
Xiaoqiu Wu ◽  
Zilong Zhao ◽  
Huarong Bai ◽  
Ting Fu ◽  
Chao Yang ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
In Vivo Imaging ◽  
Dna Aptamer ◽  
Ductal Adenocarcinoma

scholarly journals Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 985
Author(s):  
Jun Young Park ◽  
Ju Ri Chae ◽  
Ye Lim Cho ◽  
Youndong Kim ◽  
Dasom Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Delivery ◽  
Binding Affinity ◽  
Cell Lines ◽  
Dna Aptamer ◽  
A431 Cells ◽  
In Vivo Models ◽  
Huh7 Cells ◽  
Xenograft Models

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver, which can progress rapidly and has a poor prognosis. Glypican-3 (GPC3) has been proposed to be an important diagnostic biomarker and therapeutic target for HCC. Aptamers have emerged as promising drug delivery vehicles because of their high binding affinity for target molecules. Herein, we developed G12msi, a gemcitabine-incorporated DNA aptamer, targeting GPC3, and evaluated its binding specificity and anti-tumor efficacy in GPC3-overexpressing HCC cell lines and murine xenograft models. GPC3-targeted aptamers were selected by using the SELEX process and the chemotherapy drug gemcitabine was internally incorporated into the aptamer. To determine the binding affinity and internalization of the G12msi, flow cytometry and confocal microscopy were performed on GPC3-positive HepG2, Hep3B, and Huh7 cells, as well as a GPC3-negative A431 cell. The anti-tumor activities of G12msi were evaluated with in vitro and in vivo models. We found that G12msi binds to GPC3-overexpressing HCC tumor cells with high specificity and is effectively internalized. Moreover, G12msi treatment inhibited the cell proliferation of GPC3-positive HCC cell lines with minimal cytotoxicity in control A431 cells. In vivo systemic administration of G12msi significantly inhibited tumor growth of HCC HepG2 cells in xenograft models without causing toxicity. These results suggest that gemcitabine-incorporated GPC3 aptamer-based drug delivery may be a promising strategy for the treatment of HCC.

In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody

1995 ◽  
Vol 22 (4) ◽  
pp. 497-504 ◽  
Author(s):  
Andrew M. Scott ◽  
Eddie Rosa ◽  
Bippin M. Mehta ◽  
Chaitanya R. Divgi ◽  
Ronald D. Finn ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Nude Mice ◽  
In Vivo Imaging ◽  
Multidrug Resistant ◽  
Specific Targeting ◽  
P Glycoprotein

708 Early diagnosis of hepatocellular carcinoma by in vivo imaging

2015 ◽  
Vol 51 ◽  
pp. S129-S130
Author(s):  
X. Liang ◽  
H. Wang ◽  
Y. Zhu ◽  
J. Grice ◽  
X. Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Diagnosis ◽  
In Vivo Imaging

In vivo imaging of β-galactosidase stimulated activity in hepatocellular carcinoma using ligand-targeted fluorescent probe

Biomaterials ◽  
2017 ◽  
Vol 122 ◽  
pp. 83-90 ◽  
Author(s):  
Eun-Joong Kim ◽  
Rajesh Kumar ◽  
Amit Sharma ◽  
Byungkwon Yoon ◽  
Hyun Min Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Fluorescent Probe ◽  
In Vivo Imaging
Sign in / Sign up

Export Citation Format

Share Document